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Background: Pressure ulcers (PUs) are complications of serious acute/chronic illness. Specialist mattresses
used for prevention lack high quality effectiveness evidence. We aimed to compare clinical and cost effective-
ness of 2 mattress types.
Methods: Multicentre, Phase III, open, prospective, parallel group, randomised controlled trial in 42 UK sec-
ondary/community in-patient facilities.
2029 high risk (acutely ill, bedfast/chairfast and/or Category 1 PU/pain at PU site) adult in-patients were
randomised (1:1, allocation concealment, minimisation with random element) factors including: centre, PU
status, facility and consent type. Interventions were alternating pressure mattresses (APMs) or high speciﬁca-
tion foam (HSF) for maximum treatment phase 60 days. Primary outcome was time to development of new
PU Category 2 from randomisation to 30 day post-treatment follow-up in intention-to treat population.
Trial registration: ISRCTN 01151335.
Findings: Between August 2013 and November 2016, we randomised 2029 patients (1016 APMs: 1013 HSF)
who developed 160(7.9%) PUs. There was insufﬁcient evidence of a difference between groups for time to
new PU Category 2 Fine and Gray Model Hazard Ratio HR = 0.76, 95%CI0.561.04); exact P = 0.0890; abso-
lute difference 2%). There was a statistically signiﬁcant difference in the treatment phase time to event sensitiv-
ity analysis, Fine and Gray model HR = 0.66, 95%CI, 0.460.93; exact P = 0.0176); 2.6% absolute difference).
Economic analyses indicate that APM are cost-effective.
There were no safety concerns.
Interpretation: In high risk (acutely ill, bedfast/chairfast/Category 1 PU/ pain on a PU site) in-patients, we found
insufﬁcient evidence of a difference in time to PU development at 30-day ﬁnal follow-up, which may be related to
a low event rate affecting trial power. APMs conferred a small treatment phase beneﬁt. Patient preference, low PU
incidence and small group differences suggests the need for improved targeting of APMs with decision making
informed by patient preference/comfort/rehabilitation needs and the presence of potentially modiﬁable risk fac-
tors such as being completely immobile, nutritional deﬁcits, lacking capacity and/or altered skin/Category1 PU.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Pressure ulcers (PUs) have detrimental impacts on patients' physi-
cal, social and psychological health including increased care burden,
Research in context
Evidence before this study
Pressure-relieving mattresses are a key component of pressure
ulcer prevention practice and lack of evidence of comparative effec-
tiveness may lead to widespread adoption of ‘high tech’ solutions
(vs ‘low tech’) without demonstrated patient beneﬁt. A Cochrane
systematic review of support surfaces was available at trial inception
and updated in 2015. The latter identiﬁes 5 Randomised Controlled Tri-
als (RCTs) demonstrating evidence that a ‘low-tech’ mattress type,
High Speciﬁcation Foam (HSF) confers beneﬁt over ‘standard’ hospi-
tal foam mattresses (overall relative risk reduction of 60% (95%Con-
ﬁdence Interval (CI) 26% to 79%), hence they are recommended in
national and international guidelines as a minimum prevention
intervention for patients at risk of Pressure Ulcer development. The
Cochrane review also identiﬁed 10 RCTs comparing a ‘high-tech’
group of interventions, (Alternating Pressure Mattresses (APMs))
versus HSF/other constant low pressure mattresses and a meta-
analysis found no evidence of a difference (9 trials, overall relative
risk of developing PUwith APM0.85 (95%CI 0.64 to 1.13)). However,
only one RCT directly compared APMs and HSF plus 4 hourly turn-
ing and found no evidence of a difference. Despite the lack of evi-
dence APMs are in common use for prevention of pressure ulcers.
Qualitative data from one large RCT and feedback from the
Pressure Ulcer Research Service User Network (PURSUN) sug-
gests some patients do not like APMs (due to pump noise/soft air
cells impacting upon sleep, creating an unsafe feeling, restricting
movement, exacerbating existing balance/mobility problems and
increasing care burden/reducing ability to self-move).
A research recommendation from the National Institute of
Health and Care Excellence (NICE), uncertainty of clinical and
cost effectiveness, clinicians and patient preferences and a con-
siderable difference in unit costs of both these most commonly
used types of mattresses conﬁrmed that an RCT was necessary.
Added value of this trial
PRESSURE 2 is the largest pragmatic RCT of pressure reliev-
ing mattresses undertaken world-wide and the only direct
comparison of ‘high tech’ APMs and ‘low tech’ HSF. We report
time to development of new Category 2 PUs and cost effec-
tiveness to 30 days post treatment. Our trial provides approxi-
mately 80% of the data for the comparison of APMs and HSF,
with 160 new Category 2 PU events in 2029 patients. There was
insufﬁcient evidence of a difference between APM and HSF in
time to event at the end of trial follow-up: a pre-planned treat-
ment phase sensitivity analysis identiﬁed early beneﬁt of APM
vs HSF, which diminished in the long-term/primary outcome.
This is the ﬁrst trial to compare mattress safety and report
detailed reasons for non-compliance which demonstrated no
differences in the safety proﬁle of APMs and HSF (i.e., ruled out
harm), but compliance data highlighted that more patients
requested a change from APM due to comfort or to aid move-
ment compared to HSF.
Finally, this is the ﬁrst study in the ﬁeld to include an
exploratory moderator analysis to assess potential modiﬁable
factors by mattress group interactions in the primary model
and these included altered and Category 1 skin status, complete
immobility, nutritional deﬁcits and lack of capacity.
Implications of all the available evidence
In patients who were at high risk of PU development: acutely
ill in-patients, who were bedfast/chairfast and/or had an existing
Category 1 PU (or pain on a PU site), we found insufﬁcient evi-
dence of a difference in time to PU development at the end of trial
follow-up. However, APMs did confer a small treatment phase
time to event beneﬁt. Given the small absolute differences during
treatment (2.6%) and long-term follow-up (2%), patient APM
compliance and very low PU incidence rate observed (7.9%), there
is a trade-off between using APMs and HSF. We recommend
work on improving the personalisation of mattress type. This
should take into account patient preferences, rehabilitation needs
and the presence of risk factors which may be modiﬁable. Those
gaining more potential beneﬁt from APM are likely to be
completely immobile, have nutritional deﬁcits, lack capacity and/
or have altered skin/Category1 PU.
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symptoms of pain, exudate and odour [1]. PUs are prevalent in the
health-care sector [2] and as the elderly population increases and
advances in medical care lead to increased long-term disability bur-
den and complexity in patient management, improving the evidence
base for improvements in their prevention is a priority. As well as
high personal costs incurred by patients there are also high ﬁnancial
costs incurred by healthcare funders and providers in the treatment
of PUs due to increased length of hospital stay, hospital admission,
community nursing, treatments (reconstruction surgery/ mattresses/
dressings/ technical therapies) and complications (serious infection)
[3].
They manifest when mechanical load applied to soft tissues
causes cell deformation leading to cell membrane rupture and/or
impairment of the blood supply and tissue ischaemia, both resulting
in tissue damage [4].
A priority in clinical practice is prevention of PUs through reposi-
tioning (to intermittently completely off-load high risk skin areas)
and provision of specialist mattresses/cushions to reduce mechanical
load [5,6]. In relation to specialist mattresses, systematic review evi-
dence [7] supports guideline recommendations that high speciﬁca-
tion foam (HSF) mattresses are used as a minimum for high risk
patients to prevent PUs [5,6]. The McInnes et al. review [7] identiﬁed
11 RCTs comparing alternating pressure mattresses (APMs) with con-
stant low pressure mattresses and a meta-analysis of 10 showed no
evidence of a difference.
Despite the lack of evidence APMs are recommended in guidelines
for patients where HSF is failing [5] or repositioning is not possible
[6] and they are in widespread clinical use.
However, lived experience studies [1], secondary trial data [8] and
feedback from the PU Research Service User Network (PURSUN)
(http://medhealth.leeds.ac.uk/pursun accessed 06.08.18) suggests
some patients do not like APMs (due to pump noise/soft air cells
impacting upon sleep, creating an unsafe feeling, restricting move-
ment, exacerbating existing balance/mobility problems and increas-
ing care burden/reducing ability to self-move [8]. More recently a
network meta-analysis reported that APMs had the lowest probabil-
ity of being the most comfortable compared to other mattress types
[9].
To address clinical uncertainty this pragmatic real world evalua-
tion was designed to compare the clinical and cost effectiveness of
two functionally distinct mattress types: ‘high tech’ alternating pres-
sure mattresses (APMs) and ‘low tech’ high speciﬁcation foam (HSF)
[7].
The primary objective was to compare time to developing a new
PU Category 2 by 30 days post end of treatment phase. Secondary
objectives were to compare: time to developing a new PU Category
1; time to developing a new PU Category 3; time to healing of all
pre-existing Category 2 PUs; mattress compliance; safety; impact on
health related quality of life and incremental cost effectiveness.
Table 1
Additional skin classiﬁcations.
Category Description
Category A
Alterations to
intact skin
Alterations to intact skin. Please specify with sub-category code:
001 = Blanching redness
which persists
011 = Papery thin
002 = Bruising  red hue 012 = Cracks/calloused
003 = Bruising  purple hue 013 = Spongy
004 = Scar 014 =Macerated
005 = Oedema 015 = Scratches
006 = Cellulitis 016 = Rash
007 = Lymphodema 017 = Scab
008 = Discoloration 
ischaemia
018 = Induration
009 = Discoloration 
cyanosis
019 = Heat
010 = Dry/ﬂaky 999 = None of the above, please
describe
Category N/A
Not applicable
Specify with sub-category code:
001 = Amputation 007 = Device-related ulcer
002 = Bandage in situ 008 = Surgical wound/bruising
003 = Cast in situ 009 = Traumatic
wound/bruising
004 = Dressing in situ 010 = Dermatological skin
condition e.g. eczema
005 = Incontinence
associated dermatitis
011 = Unable to assess
006 = Other chronic wound 999 = None of the above, please
describe
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2.1. Study Design
This was designed as a multicentre, Phase III, open, prospective,
double triangular group sequential, parallel group, randomised con-
trolled trial (RCT), with two planned interim analyses providing the
possibility of early stopping for either futility or inferiority. The trial
protocol is published [10] and summary methods detailed.
The trial, approved by Leeds West Research Ethics Committee (13/
YH/0066), was monitored by an independent Trial Steering Commit-
tee (TSC) and Data Monitoring Committee (DMC).
2.2. Participants
The trial was promoted to centres through national networks and
any organisation with sufﬁcient access to trial eligible mattresses
(see eDocument 1) and electric proﬁling beds were able to take part
in the trial.
Patients were recruited from adult secondary care and commu-
nity in-patient acute admission facilities in the UK (facilities are
deﬁned in eDocument 2). Prior to recruitment patients could be lay-
ing on any type of mattress. Consent was obtained though written/
witnessed verbal consent or consultee agreement (see eDocument 3).
Patients were eligible if they were: in-patient with evidence of
acute illness [10];  8 years; expected stay 5 days; expected to
comply with follow-up; on electric proﬁling bed-frame; high PU risk
due to at least one of following:
a) Braden Activity score 1/2 ANDMobility score 1/2 [11,12]
b) Category 1 PU [12]
c) Localised skin pain on a healthy/altered/Category 1 pressure area
[13].
Patients were excluded if they: had previously participated; cur-
rent/previous PU Category 3; planned ICU admission; unable to
receive intervention; outwith mattress weight limits (<45 kg
or> 180 Kg); ethically inappropriate e.g. thought to be in the last few
days of their life.
Since a large proportion of patients suffering from or at risk of
PUs have cognitive impairment and this impacts upon under-
standing and compliance with repositioning and self-care, includ-
ing ability to reposition independently using the electric proﬁling
beds, inclusion of patients who lacked capacity was necessary to
ensure the study population was generalisable to a usual clinical
population. Ethical approval was obtained to include patients
who lacked capacity.
2.3. Randomisation and Masking
Participants were randomised centrally (24 h automated tele-
phone system, ensuring allocation concealment) on a 1:1 basis using
minimisation (with random element) and minimisation factors: cen-
tre, PU status, type of facility, and type of consent. Following random-
isation the patient was expected to be transferred to the allocated
mattress within 24 h. Full details of randomisation and allocation
procedures are given in eDocument 4.
Blinding of the research and clinical staff or patients was not pos-
sible due to the appearance of the mattresses. Assessment of risk of
bias of the primary endpoint was done with central blind review of
photographs and a 10% sample of patients who had skin assessments
by a practitioner blinded to previous assessments was performed.
Details of methods are provided elsewhere [14].2.4. Procedures
Patients were allocated to APM or HSF mattress for a maximum
60 day treatment phase (or until discharge, or no longer at risk), in
conjunction with electric proﬁling bed frames. Treatment follow-up
was twice weekly to day 30 and weekly from day 3160 and there
was a post treatment 30 day ﬁnal follow-up.
Mattress speciﬁcations were deﬁned (eDocument 1) and utilised
from usual hospital supplies, maximising generalisability.
Participant recruitment and assessments were conducted by
trained dedicated Clinical Research Nurse/Practitioners (CRN/P),
employed by the local centre and independent of the ward teams.
The assessment schedule was as follows:
Baseline only: risk factors were recorded using the PU Minimum
Data Set [12,15].
Baseline and follow-up visits: a) skin status, assessed on 14 ana-
tomical sites including PU classiﬁcation [6], additional descriptors of
alterations to intact skin and skin site exclusions (Table 1 and eDocu-
ment 6) [12] and pain [13], b) PU prevention measures (e.g. reposi-
tioning frequency) and c) expected adverse events/serious adverse
events (AEs/SAEs) including death, hospital re-admission, device-
related ulcers and falls and ‘related’ and ‘unexpected’ SAEs (RUSAEs).
Daily: mattress compliance (including which mattress the patient
was on and whether, if it had dual function, it was in APMmode) was
recorded during the treatment phase.
Baseline, week 1, week 3 and post treatment 30 day ﬁnal follow-up:
a generic QOL instrument EuroQol-5Dimension-5 Level (EQ-5D-5 L)
[16] and condition speciﬁc utility measure Pressure Ulcer-Quality of
Life-Utility Index (PU-QOL-UI) [17,18] were researcher administered
with a healthcare resource utilisation questionnaire (combining health-
care records and patient reported sources).
2.5. Outcomes
The primary outcome was time to developing a new PU Category
2 from randomisation to 30 days from the end of the treatment
phase (maximum of 90 days).
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1. Time to developing a new PU Category 3 from randomisation to
trial completion
2. Time to developing a new PU Category 1 from randomisation to
trial completion
3. Time to healing of all pre-existing Category 2 PUs from random-
isation to trial completion
4. Mattress change during the treatment phase
5. Adverse events
Secondary objectives (Health Economic)
1. Health related quality of life (QOL) using SF-12 and PU-QoL-P
instruments
2. Incremental cost-effectiveness of APM compared to HSF from the
perspective of the health and social care sectors using EQ-5D-5 L
and health and social care resource utilisation questionnaire
PUs were classiﬁed using the 2009 National Pressure Ulcer Advi-
sory Panel/European Pressure Ulcer Advisory Panel (NPUAP/EPUAP)
[19] system. In the absence of a PU, additional descriptors were
recorded including ‘healthy intact skin’, alterations to intact skin
(referred to as Category A for data recording purposes) and ‘not appli-
cable’ as detailed in Table 1.
2.6. Sample Size and Statistical Analysis
588 events (~2954 patients) were required for 90% power, 5% dif-
ference (APM 18% vs HSF 23%, corresponding hazard ratio 0.759), 5%
2-sided signiﬁcance level, 6% loss to follow-up [8,13,20] accounting
for multiplicity in interim analyses using Lan-DeMets a and b spend-
ing functions [21]. Event driven interim analyses were planned (300
and 445 events) and a Value of Information (VOI) Analysis if futility
boundary was crossed; futility boundaries were non-binding.
The trial recruited participants at a much slower rate than antici-
pated and an unplanned interim analysis and VOI Analysis using con-
ﬁdential trial data was requested by the funder and conducted in
November/December 2015 on 909 participants. Unblind analyses
were reviewed by the DMC and remained conﬁdential. The DMC
informed the Independent TSC that the event rate was much lower
(9.9%) than originally estimated. The DMC and TSC asked the Trial
Management Group (TMG) who remained blind to the event rate, to
consider the minimum clinically relevant differences on varying cen-
tred event rates of 15%, 10% and 5%. The preferred TMG option was a
funded extension to detect absolute differences of 3.75%, 3.3% and
2.5% (relative differences of 25%, 33.3% and 50%) respectively, which
were considered to be the minimum clinically important differences.
The TMG also noted that a no cost extension to detect absolute differ-
ences of 5%, 4% and 3% (relative difference of 33.3%, 40% and 60%)
respectively were considered of clinical relevance. The funder agreed
to a no cost recruitment extension with a ﬁnal minimum recruitment
target of 1996 patients, under a revised assumption of an overall
event rate of 10%, absolute difference of 4% (corresponding HR of
0.652) with 80% power, requiring 172 events to be observed. This
resulted in the trial design being modiﬁed to have one ﬁnal analysis.
Further details of the review process, analysis and recommendations
can be found in eDocument 5.
Analyses were performed using SAS version 9.4 (SAS Institute Inc.,
Cary, NC, USA) and pre-approved statistical analysis plan (eDocument
6). All participants recruited were included using ‘Intention-To-Treat’
(ITT) and analysed by randomised allocation.
The Fine and Gray [22] model (accounting for death and withdrawal
due to clinical condition as competing risks) was ﬁtted to the primary
and secondary time to event endpoints and the planned treatment
phase sensitivity analysis with adjustment for minimisation factors
(except centre), presence of pain and presence of a condition affecting
peripheral circulation; a likelihood ratio test was used to assess theeffect of mattress group. Corresponding hazard ratios (HR), 95% conﬁ-
dence intervals (CI) and P-values are reported, and cumulative inci-
dence of PU Category 2 development presented bymattress group.
AEs/SAEs and RUSAEs were summarised using descriptive statistics.
Analysis of data from the ‘Per Protocol’ population was undertaken.
An exploratory moderator analysis was also undertaken to assess
potential risk factor by mattress group interactions in the primary
model.
A mediator analysis was planned to identify potential mediators,
such as mattress compliance and patient repositioning, however
methods for competing risks data are currently under developed and
therefore only descriptive summaries were produced.
To meet the health economic objectives, an ITT analysis used qual-
ity adjusted life years (QALYs) as the main outcome and adopted the
perspective of the UK National Health Service (NHS) and Personal
Social Services (PSS). The NICE £20,000 per QALY gained threshold
was used to determined cost-effectiveness. Utility values were
derived from the EQ-5D-5L [23], and costs were estimated using the
UK tariff [23]. Multiple imputation was used to provide data for all
patients and incremental cost effectiveness ratios (ICERs) reported.
Costs and outcomes were adjusted for baseline imbalances using
multiple regression analysis. Adjustment was made by utility at base-
line (for outcomes only), PU status, setting, peripheral circulation and
presence of pain. Sampling uncertainty was determined via a proba-
bilistic sensitivity analysis (PSA) using a non-parametric bootstrap
[2426]. Additional sensitivity analyses were undertaken using
QALYs estimated from the PUQOL-UI and complete cases only [18].
ISRCTN 01151335 URL: https://www.isrctn.com/search?
q=011513352.7. Role of Funding Source
This project was funded by the National Institute for Health
Research (NIHR) Health Technology Assessment (HTA) programme
(project number 11/36/33). The funder monitored recruitment,
requested an unplanned interim and VOI analysis, reviewed the VOI
analysis and the recommendations of the TSC and DMC for trial con-
tinuation and made the ﬁnal decision for an unfunded time extension
to meet the revised minimum of 1996 participants.3. Results
Between 1st August 2013 and 30th November 2016, 15,277
patients were screened (Fig. 1) from 39 English NHS Trusts/Scottish
Health Boards (total 47 centres, comprising 25 teaching hospitals, 13
general hospitals and 9 community hospitals). Of those screened,
5077(33.2%) patients were eligible of whom 2068(40.7%) consented
and 2030(40.0%) were randomised to APMs (1017, 50.1%) and HSF
(1013, 49.9%), Fig. 1.
Screened and randomised populations were similar in age, gender
and ethnicity but not by ward allocated mattress type. At screening,
7640(50.0%) patients were on APM or other ‘high tech’ and 7462
(48.8%) patients were on HSF or other ‘low tech’, whereas, of those
randomised 868(42.8%) were on APM and 1149(56.6%) were on HSF,
reﬂecting greater staff unwillingness to randomise patients already
provided with an APM (Table 3).
Patient disposition was balanced across groups including, with-
drawals (APM 6.1%, HSF 5.6%) and deaths (APM 8.1%, HSF 8.3%)
(Fig. 1). One patient randomised twice, was withdrawn and the sec-
ond randomisation excluded from the ITT population (n = 2029).
Patient characteristics and pre-randomisation preventative care
interventions were balanced across groups (Table 2, Table 3 and
Table 7a in eDocument 7).
The trial comprised largely of elderly patients (median 81 years,
range 21105), 1119 (55.2%) were female and 1992 (98.2%) of white
Fig. 1. Consort diagram.
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Table 2
Baseline characteristics of the intention-to-treat population.
Attribute APM
n = 1016
HSF
n = 1013
Overall
n = 2029
Gender
Male 462(45.5%) 445(43.9%) 907(44.7%)
Female 553(54.4%) 566(55.9%) 1119(55.2%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Age (years)
Mean (S.D.) 77.8(13.42) 78.2(12.87) 78.0(13.1)
Median (range) 81(21.1105) 81(21.9101) 81(21,105)
IQR (71.3,87.0) (71.9,87.2) (71.6,87.1)
Missing 0 0 0
Ethnicity
White 1000(98.4%) 992(97.9%) 1992(98.2%)
Mixed race/non-white 15(1.5%) 19(1.9%) 34(1.7%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Medical speciality
Medical 641(63.1%) 669(66.1%) 1310(64.6%)
Surgical 83(8.2%) 72(7.1%) 155(7.6%)
Orthopaedics and trauma 233(22.9%) 220(21.7%) 453(22.3%)
Oncology 21(2.1%) 16(1.6%) 37(1.8%)
Critical care 10(1.0%) 6(0.6%) 16(0.8%)
Neurosciences 17(1.7%) 15(1.5%) 32(1.6%)
Spinal injury 8(0.8%) 9(0.9%) 17(0.9%)
Other 2(0.2%) 2(0.2%) 4(0.2%)
Missing 1(0.0%) 4(0.3%) 5(0.2%)
Consent type
Written 706(69.5%) 696(68.7%) 1402(69.1%)
Witnessed verbal 151(14.9%) 152(15.0%) 303(14.9%)
Consultee agreement 159(15.6%) 163(16.1%) 322(15.9%)
Missinga 0(0.0%) 2(0.2%) 2(0.1%)
Healthcare setting
Secondary care hospital 710(69.9%) 704(69.5%) 1414(69.7%)
Community hospital 191(18.8%) 188(18.6%) 379(18.7%)
NHS intermediate care/
rehabilitation facility
115(11.3%) 119(11.7%) 234(11.5%)
Missingb 0(0.0%) 2(0.2%) 2(0.1%)
Days between admission to
randomising
Mean (S.D.) 12.7(20.27) 13.3(21.23) 13.0(20.8)
Median (range) 6(0.0,306) 7(0.0,388) 7(0,388)
IQR (3.0,15.0) (3.0,17.0) (3.0,16.0)
Missing 1 2 3
Standard deviation (SD), Inter-Quartile Range (IQR).
a These were entered on the 24 h system as written consent, and therefore included
in the analyses.
b These were entered on the 24 h system as Secondary care hospital, and therefore
included in the analyses,
Table 3
Baseline PU prevention interventions.
Interventions APM
n = 1016
HSF
n = 1013
Overall
n = 2029
Current mattress type
HSF or other ‘low tech’ 575(56.6%) 574(56.7%) 1149 (56.6%)
APM or other ‘high tech’ 435(42.8%) 433(42.7%) 868(42.8%)
Missing 6(0.6%) 6(0.6%) 12(0.6%)
Frequency of repositioning in last
24 h
More frequently than 2 hourly 148(14.6%) 146(14.4%) 294(14.5%)
23 hourly 473(46.6%) 494(48.8%) 967(47.7%)
45 hourly 333(32.8%) 307(30.3%) 640(31.5%)
67 hourly 36(3.5%) 48(4.7%) 84(4.1%)
Less frequently than 8 hourly 20(2.0%) 12(1.2%) 32(1.6%)
Missing 6(0.6%) 6(0.6%) 12(0.6%)
Time spent sat out of bed in last
24 h
N/A i.e. bedfast 270(26.6%) 271(26.8%) 541(26.7%)
Less than 2 h 91(8.9%) 90(8.9%) 181(8.9%)
23 h 134(13.2%) 134(13.2%) 268(13.2%)
45 h 178(17.5%) 183(18.1%) 361(17.8%)
67 h 125(12.3%) 128(12.6%) 253(12.5%)
More than 8 h 207(20.4%) 191(18.9%) 398(19.6%)
Missing 11(1.1%) 16(1.6%) 27(1.3%)
Type of cushion
Standard chair only 203(27.3%) 206(27.9%) 409(27.6%)
High tech specialist cushion 56(7.5%) 52(7.0%) 108(7.3%)
Low tech specialist cushion/
chair with integral pressure relief
434(58.3%) 429(58%) 863(58.2%)
Pillow 45(6.1%) 47(6.4%) 92(6.2%)
Missing 6(0.8%) 5(0.7%) 11(0.7%)
Total (number of patients who sat
out)
744(100%) 739(100%) 1483(100%)
Participant on electronic proﬁling
bedframe
Yes 1012(99.6%) 1008(99.5%) 2020(99.6%)
No 3(0.3%) 3(0.3%) 6(0.3%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Adjuvant devices and dressing
Yes 143(14.1%) 141(13.9%) 284(14.0%)
No 867(85.3%) 865(85.4%) 1732(85.4%)
Missing 6(0.6%) 7(0.7%) 13(0.6%)
J. Nixon et al. / EClinicalMedicine 14 (2019) 4252 47ethnicity. Patients were in-patients for a median of 7 (range 0388)
days pre-randomisation.
Overall 322 (15.9%) patients lacked capacity, 909(44.8%) had a his-
tory of falls in the preceding month, 1961 (96.6%) had limitations to
independent movement and 2003 (98.7%) and 1879 (92.6%) patients
were classiﬁed as ‘at risk’ of PU development on the PURPOSE-T and
Braden Scale respectively (Table 4). Subscales of Braden: Activity and
Mobility have been included as they were eligibility criteria.
There were high levels of skin morbidity including ‘worst’ PU/skin
status of 7.1%(n = 145) Category 2 PUs, 11.6%(n = 235) Category 1 and
66.4%(n = 1347) alterations to intact skin with 53.4%(n = 1084) report-
ing pressure area related pain (Table 5).
Of 2029 ITT population, 160 (7.9%) patients developed at least one
new PU Category 2 with an absolute difference of 2% (APM 70
(6.9%), HSF 90(8.9%)), see Table 6 with a total of 213 new PUs Cate-
gory 2 observed (APM, N = 89, HSF, N = 124). Skin sites location of
all new PUs can be found in eDocument 7b.
Where patients developed a PU Category 2, the median (range)
time to ﬁrst new PU Category 2 was APM 18 days (286) and HSF
12 days (294). There was no evidence of a difference between mat-
tress groups for the primary endpoint (time to development of PU
Category 2) in the adjusted analysis (Fine and Gray model
(HR = 0.76 (95%CI, 0.56 to 1.04; exact P = 0.0890))). Only skin statuswas statistically signiﬁcantly associated with the primary endpoint
(Wald P = 0.0057); speciﬁcally, patients with a pre-existing Category
1 PU (HR = 1.83(95% CI, 1.17 to 2.87)) and pre-existing Category 2 PU
(HR = 1.83(95% CI, 1.09 to 3.09)) were more likely to develop a new
Category 2 PU than those who did not have a Category 1 or 2 PU at
baseline (see Table 7). Fig. 2 represents the unadjusted cumulative
incidence curves for the primary and secondary analyses.
In the treatment phase sensitivity analysis, 132 (6.5%) developed
new PU Category 2 between randomisation and end of treatment
phase (APM 53(5.2%), HSF 79 (7.8%)) with a statistically signiﬁcant
difference observed in time to development of PU Category 2 in the
Fine and Gray model (HR = 0.66(95% CI, 0.46 to 0.93; exact
P = 0.0176)) (see eDocument 8a).
350 (17.2%) patients reached the secondary endpoint of develop-
ing a new PU Category 1 by 30 day ﬁnal follow-up (APM 160
(15.7%), HSF 190(18.8%)), with no evidence of a difference in the time
to event (Fine and Gray model (HR = 0.83(95% CI, 0.67 to 1.02; exact
P = 0.0733))) (see eDocument 8b).
32 (1.6%) patients reached the secondary endpoint of developing a
new PU Category 3 by 30 day ﬁnal follow-up (APM 14(1.4%), HSF 18
(1.8%)) with no evidence of a difference in the time to event (Fine and
Gray model (HR = 0.81(95% CI, 0.40 to 1.62; exact P = 0.5530)) (see
eDocument 8c)). The number of Category 3 PUs were comparable
by arm (APM N = 19 vs HSF N = 21).
Of 145 patients with a pre-existing PU Category 2 (APM 70(48.3%),
HSF 75(51.7%)), healing was observed in 89 (APM 44(62.9%); HSF 45
(60.0%)) (see eDocument 8d), with no evidence of a difference in the
Table 4
Baseline risk factors.
Risk factor APM
n = 1016
HSF
n = 1013
Overall
n = 2029
BMI
Underweight (<18.5 kg/m2) 52(5.1%) 49(4.8%) 101(5.0%)
Normal weight (18.5 to
<25 kg/m2)
455(44.8%) 392(38.7%) 847(41.7%)
Overweight (25 to <30 kg/m2) 266(26.2%) 336(33.2%) 602(29.7%)
Obese (30 kg/m2) 235(23.1%) 217(21.4%) 452(22.3%)
Missing 8(0.8%) 19(1.9%) 27(1.3%)
History of falls in the past month
Yes 458(45.1%) 451(44.5%) 909(44.8%)
No / not aware of any falls 554(54.5%) 559(55.2%) 1113(54.9%)
Missing 4(0.4%) 3(0.3%) 7(0.3%)
Analysis of independent movement
Moves frequently / Major
position changes
28(2.8%) 32(3.2%) 60(3.0%)
Moves frequently / Slight
position changes
141(13.9%) 139(13.7%) 280(13.8%)
Moves occasionally / Major
position changes
110(10.8%) 110(10.9%) 220(10.8%)
Moves occasionally / Slight
position changes
624(61.4%) 621(61.3%) 1245(61.4%)
Doesn't move 109(10.7%) 107(10.6%) 216(10.6%)
Missing 4(0.4%) 4(0.4%) 8(0.4%)
Risk status recorded on PURPOSE T
Not at risk 12(1.2%) 11(1.1%) 23(1.1%)
No PU but at risk 820(80.7%) 816(80.6%) 1636(80.6%)
PU Category 1 or scarring from
previous PU
183(18.0%) 184(18.2%) 367(18.1%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Braden Activity subscale
Walks Frequently 13(1.3%) 9(0.9%) 22(1.1%)
Walks Occasionally 108(10.6%) 113(11.2%) 221(10.9%)
Chairfast 677(66.6%) 667(65.8%) 1344(66.2%)
Bedfast 217(21.4%) 222(21.9%) 439(21.6%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Braden Mobility subscale
No Limitation 22(2.2%) 20(2.0%) 42(2.1%)
Slightly Limited 125(12.3%) 115(11.4%) 240(11.8%)
Very Limited 790(77.8%) 797(78.7%) 1587(78.2%)
Completely Immobile 78(7.7%) 79(7.8%) 157(7.7%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Overall Braden PU risk
Not at risk (>18) 78(7.7%) 69(6.8%) 147(7.2%)
At risk (18) 937(92.2%) 942(93.0%) 1879(92.6%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Table 5
Skin status at baseline.
Question APM
n = 1016
HSF
n = 1013
Overall
n = 2029
Worst category of skin reported at
baseline (patient level)
Normal Skin 147(14.5%) 152(15.0%) 299(14.7%)
Category A 673(66.2%) 674(66.5%) 1347(66.4%)
Category 1 125(12.3%) 110(10.9%) 235(11.6%)
Category 2 70(6.9%) 75(7.4%) 145(7.1%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Pressure related pain on any skin site
Yes 577(56.8%) 584(57.7%) 1161(57.2%)
No 393(38.7%) 388(38.3%) 781(38.5%)
Unable to assess 15(1.5%) 15(1.5%) 30(1.5%)
Combination of ‘missing’ and ‘no’ 6(0.6%) 6(0.6%) 12(0.6%)
Combination of ‘No’ and ‘unable
to assess
15(1.5%) 13(1.3%) 28(1.4%)
Missing 10(1.0%) 7(0.7%) 17(0.8%)
Pressure related pain on a healthy,
altered or Category 1 skin site?
Yes 541(53.2%) 543(53.6%) 1084(53.4%)
No 440(43.3%) 439(43.3%) 879(43.3%)
Unable to assess 15(1.5%) 15(1.5%) 30(1.5%)
Combination of ‘missing’ and ‘no’a 2(0.2%) 1(0.1%) 3(0.1%)
Combination of ‘No’ and ‘unable
to assessa
5(0.5%) 3(0.3%) 8(0.4%)
Missing 9(0.9%) 5(0.5%) 14(0.7%)
No skin sites reported as healthy,
altered or Category 1b
4(0.4%) 7(0.7%) 11(0.5%)
a Classiﬁed as ‘no’ in the analysis.
b Classiﬁed as ‘missing’ in the analysis.
48 J. Nixon et al. / EClinicalMedicine 14 (2019) 4252time to event (Fine and Gray model (HR = 1.12 (95% CI, 0.74 to 1.68;
exact P = 0.6122))).
There were no ‘RUSAEs’ and only 3 mattress related AEs reported.
Deaths (APM 8.1%, HSF 8.3%), re-admission rates (APM 8.1%, HSF 6.1%)
and fall rates (APM 14.9%, HSF 15.7%) were similar in both groups. Of
all 486 reported falls, 62.3% occurred after the treatment phase and
17.5% resulted in serious injury but none were mattress related.
Compliance with mattress allocation within 48h of randomisation
was reported for 81.5% of patients in each group (see eDocument 9). The
median (range) proportion of time spent on the randomisedmattress was
92% (0100%) APM and 100% (0100%) HSF. Only 94 (9.3%) APM and 110
(10.9%) HSF randomised patients never received their allocatedmattress.
Where allocated mattress was received, 24.1%(222/922) APM and
24.4%(220/903) HSF had at least one mattress change (eDocument 9),
with reasons for ﬁrst change including mattress being uncomfortable
(APM 90(40.5%), HSF 28(12.7%)); to aid rehabilitation or movement
(APM 49 (22.1%), HSF 5(2.3%)); ward transfer (APM 40(18.0%), HSF 20
(9.1%)) and clinical condition (APM 3(1.4%), HSF 130(59.1%)).
The blinded central photography sub-study [14] undertaken to
establish systematic bias in endpoint assessment found high levels of
agreement in both arms and a Prevalence and Bias Adjusted Kappa
statistic of 0.93 demonstrating ‘very good agreement’ of blinded pho-
tograph assessments compared to un-blind clinical assessments.3.1. Per Protocol Population
The per-protocol population consisted of 1352(66.6%) patients.
Patients were excluded from the per-protocol analysis for compli-
ance and eligibility reasons (not mutually exclusive) as follows;
less than 60% compliance with allocated mattress (N = 545,
26.9%), not at high risk of PU development (N = 42, 2.1%), current
or previous PU Category 3 (N = 8, 0.4%), outside weight limits
(N = 6, 0.3%), consent form was not received or consent date was
after randomisation (N = 13, 0.6%). Of the 1352 patients in the
per-protocol population, 663(49.0%) were allocated to APM and
689(51.0%) were allocated to HSF. There was no evidence of a dif-
ference between mattress groups in time to development of new
PU Category 2 for the primary endpoint (adjusted Fine and
Gray model HR (95%CI) = 0.79 (0.54 to 1.16), P = 0.2249), absolute
difference 1.2% (APM 7.2%, HSF 8.4%). In the treatment phase sen-
sitivity analysis a marginally signiﬁcant treatment effect in time
to development of new PU Category 2 was observed indicating
some evidence of a difference between mattress groups (adjusted
Fine and Gray model HR (95%CI) of 0.76 (0.32 to 1.00),
P = 0.0508), absolute difference 1.7% (APM 5.7%, HSF 7.4%).
3.2. Moderator Analysis (Exploratory Analysis)
The results of the exploratory moderator analysis of the treat-
ment effects for each level of each covariate (risk factor) for the
primary endpoint are presented in Fig. 3. The Forest plots present
the point estimate of the treatment effect, ln(HR), together with
the corresponding 95% CI, alongside the plot, the corresponding
HR and 95% CIs. Incidence rates observed within each level of
risk factor are aligned with the PU conceptual framework [4] and
whilst there is no evidence of differential treatment effects within
risk factors at the 5% signiﬁcance level, treatment effects from
these exploratory analyses suggest that there may be a potential
beneﬁt of APM vs HSF in patients whose worst skin status was
assessed as altered or PU Category 1; those with mobility
Table 6
Number of patients developing a new PU Category 2 at post treatment 30 day ﬁnal follow-up.
Mattress New PU
Cat 2
No new PU Category 2 Baseline
Assessment
not eligible
Total
No Died Withdrawn
APM 70(6.9%) 825(81.2%) 77(7.6%) 40(3.9%) 4(0.4%) 1016 (100%)
HSF 90(8.9%) 812(80.2%) 72(7.1%) 31(3.1%) 8(0.8%) 1013 (100%)
Overall 160(7.9%) 1637(80.7%) 149(7.3%) 71(3.5%) 12(0.6%) 2029 (100%)
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participated via consultee agreement.3.3. Mediator Analysis (Exploratory Analysis)
Throughout the treatment phase at least 50% of patients in both
APM and HSF arms at each visit with complete data were reposi-
tioned 23 hourly or more frequently. However, the proportion of
patients repositioned 23 hourly or more frequently appears to
reduce during the treatment phase in both arms (eDocument 10).3.4. Health Economics
The mean total health care costs of using APMwas lower than HSF
(£4482; 95% CI £4438£4526 vs £4621; 95% CI £4577£4665;
P< 0.000), this despite the APM mattress being more costly as the
biggest proportion of the costs (around 60%) correspond to in-patient
care (APM £2810.08; HSF £2888.68) (eDocument 11 Health Economic
Analysis). In terms of outcomes, the mean estimated QALYs were
higher for APM than HSF (0.128; 95% CI 0.1260.130 vs 0.127 95% CI
0.124129; P = 0.47). Although the negligible difference in QALYs,
the difference in costs between the two alternatives drive the cost-
effectiveness towards APM.
The results of the PSA conﬁrm those of the deterministic analysis
as in 99% of the 10,000 Monte Carlo simulations APM is cost-saving,
whilst in 77% APM it produces more QALYs than HSF. Although in
some cases (33% iterations) HSF produces more QALYs, its higher cost
overcome these gains. Therefore, the PSA estimates indicate that
APM has a 99% probability of being cost effective at a threshold of
£20,000 (eDocument 11 Health Economic Analysis).
The results of the sensitivity analyses using QALYs derived from
the PUQOL-UI were in the same direction as when derived from the
EQ-5D-5L (eDocument Health Economic Analysis).Table 7
Time to development of new PU Category 2 by 30 day ﬁnal follow-up.
Covariate Level of covariate Incidenc
Treatment HSF 90/1013
APM 70/1016
Skin status No PU 115/164
PU Category 1 27/236 (
PU Category 2 18/145 (
Consent type Written 100/140
Witnessed verbal 32/303 (
Consultee agreement 28/322 (
Setting Secondary care hospital 102/141
Community hospital 34/379 (
NHS intermediate care/ rehabilitation facility 24/234 (
Pain on a healthy, altered or
PU Category 1 skin site
No 67/890 (
Yes 90/1084
Unable to assess 1/30 (3.3
Missing 2/25 (8.0
Presence of condition affecting
peripheral circulation
No 120/156
Yes 39/455 (
Missing 1/7 (14.3
* P-values obtained from corresponding likelihood ratio tests for the effect of treatment is4. Discussion
Overall, only 7.9% of patients recruited to the PRESSURE 2 trial
developed one or more new Category 2 pressure ulcers. The point
estimate of the hazard ratio suggests a beneﬁt of APM over HSF but
the trial was underpowered for the primary 30 day post treatment
phase endpoint due to the low number of PU events and the time to
event difference observed was not statistically signiﬁcant different
between mattress groups. All analyses were in the same direction as
the primary endpoint and the treatment phase sensitivity analysis
demonstrated small but signiﬁcant early beneﬁt of APM vs HSF.
Importantly, all analyses ruled out harm.
The long-term outcome was considered the most important for
the NHS and it appears that the early beneﬁt of the APM in the
delayed onset of new PUs during the treatment phase, is diminished
following treatment phase cessation and can be explained by cross
over, increased population heterogeneity post-acute illness and vari-
ation in post discharge prevention provision.
PRESSURE 2 is the largest randomised controlled mattress trial
undertaken world-wide, and results are consistent with the study by
Vanderwee [20] and colleagues who reported new Category 2 PU
incidence rates of 15.3% for APM and 15.6% for HSF plus turning. Our
trial provides approximately 80% of the data for the comparison of
APMs and HSF, with 160 events in 2029 patients, with Vanderwee
[20] providing data on 69 events in 447 patients.
Despite the negligible difference in QALYs equating to around half
a quality adjusted life day, the difference in costs between the two
alternatives drive the cost-effectiveness towards APM. Overall esti-
mates suggest that APM has a 99% probability of being cost-effective
at a £20,000 per QALY gained threshold.
Overall, mattress compliance was good and balanced across both
groups for numbers not receiving randomised mattress, numbers
receiving randomised mattress within 2 days and median time on
randomised mattress. As such compliance was better than expectede Reference level HR point
Estimate
HR 95%Wald
Conﬁdence limits
Wald
P-value
(8.9%)     0.0890*
(6.9%) vs HSF 0.76 0.56 to 1.04
8 (7.0%)     0.0057
11.4%) vs No PU 1.83 1.16 to 2.87
12.4%) vs No PU 1.83 1.09 to 3.09
4 (7.1%)     0.3025
10.6%) vs Written 1.34 0.90 to 1.99
8.7%) vs Written 1.23 0.79 to 1.91
6 (7.2%)     0.6182
9.0%) vs Secondary care hospital 1.06 0.71 to 1.58
10.3%) vs Secondary care hospital 1.26 0.79 to 1.99
7.5%)     0.5070
(8.3%) vs No 1.15 0.82 to 1.61
%) vs No 0.38 0.05 to 2.94
%) vs No 2.02 0.43 to 9.45
7 (7.7%)     0.5688
8.6%) vs No 1.09 0.75 to 1.57
%) vs No 2.91 0.35 to 24.51
0.0890.
Fig. 2. a-d: Survival analysis (Cumulative incidence functions for time to development of PUs).
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across groups. Of note, however, is that the reason for ﬁrst mattress
change was imbalanced across groups with a higher proportion of
patient and ward led changes from APMs due to comfort and to aid
movement/rehabilitation and a higher proportion of ward led changes
from HSF due to clinical condition, suggesting issues with equipoise
amongst clinical staff who ‘upgraded’ from HSF where patient condi-
tion deteriorated, patient preference for HSF in relation to comfort and
both ward and patient preference for HSF where patient rehabilitation
was a therapy priority. Analyses of the Per Protocol Population which
retained only patients who were compliant with their mattress alloca-
tion were consistent with the primary ITT analyses suggesting that
these issues did not impact on the overall trial conclusions.
Risk factors found to be predictive of PU development in the
adjusted analysis (Tables 8a8c in eDocument 8: Additional resultstables) are in line with previous work and adds to the growing body
of evidence that a key risk factor in immobile patients is skin status
including presence of Category 1 and Category 2 PU [6,9,12].
No safety concerns were indicated for either APMs or HSF. Con-
cerns expressed in previous research by patients about feeling unsafe
on APMs [8] were not reﬂected in falls which were balanced across
groups and consistent with those reported in acutely ill hospital pop-
ulations [27] and community dwelling settings.
The trial recruited more slowly than originally anticipated leading
to a smaller sample size than the planned maximum sample size
(2029 compared to 2954 patients), with fewer events (160 compared
to 588) and was therefore underpowered under the original trial
design assumptions. Under the revised design, the trial had 80%
power for detecting a difference of 4% between mattress groups
assuming an overall event rate of 10% with corresponding hazard
Fig. 3. Moderator analysis (Forest plots of effect size within subgroups).
J. Nixon et al. / EClinicalMedicine 14 (2019) 4252 51ratio of 0.652. The overall event rate observed was lower at 7.9% with an
absolute difference of 2.0% betweenmattress groups, and corresponding
hazard ratio of 0.76. The a priori discussions with the TMG on the
revised minimum clinically important difference for varying overall
event rates (3.3% difference for 10% event rate, 2.5% difference for 5%
event rate— see Methods and eDocument 5) suggest that the difference
observed may not be considered to be clinically important. If APMs
were allocated to patients fulﬁlling the trial inclusion criteria, the differ-
ence equates to a Number Needed to Treat (NNT) of 50. That means that
for every 50 patients allocated an APM it will beneﬁt only 1 patient.
The event rate (7.9%) was considerably lower than the sample size
estimate of 20.5%, based upon contemporary studies [7,8,13]. A key
question is whether the low rate was because: the patient population
was ‘low risk’ due to issues around selection bias and/or; it reﬂects
general improvements in clinical practice resulting from national
level PU improvement targets.
Recruitment of 40.7% of eligible patients is in line with the contem-
porary studies and in terms of ‘low risk’, despite a lack of equipoise by
ward staff (i.e., unwilling to change mattress) the randomised patient
population were similar to the previous study populations [8,13] and
characterised by acute illness, old age, high levels of pre and post ran-
domisation falls, and high levels of adverse skin status at baseline, with
higher proportions of patients lacking capacity [8].
The impact of general improvements in practice resulting from
national targets is difﬁcult to elicit from national monitoring, due to
problems of data accuracy [2] and difﬁcult interpretation of AE data [28].
A key observation is the low proportion of patients with a Category 1 PU
at baseline who subsequently developed a new Category 2 PU (11.4%)
compared to other studies which report rates of circa 33% [8,12,13].
Overall, the conclusion drawn is that the patient population were
high risk and that the low incidence observed reﬂected the prevailing
improvements in PU prevention care in the participating centres.
A key issue raised by members of the Pressure Ulcer Research Ser-
vice User Network during a results interpretation event was ‘given
the low incidence and the disadvantages of APMs in terms of impact
upon independent movement and comfort, who will beneﬁt mostfrom APMs’. As previously indicated the adjusted analysis indicates
that a key predictor of new Category 2 PU development in the study
population characterised by high levels of immobility, was the pres-
ence of Category 1 and Category 2 PUs at baseline. In addition, the
moderator analysis was included in order to explore the potential
beneﬁt of each mattress on patients with known PU risk factors.
Direct application of this analysis to practice must be undertaken
with caution since it was exploratory and interactions with mattress
allocation were non-signiﬁcant, but the results suggest that the
impact of altered and Category 1 PU skin status, complete immobility,
nutritional deﬁcits and the vulnerability afforded by lack of capacity
may be modiﬁable as risk factors through use of the APMs. Given the
low event rate this may help clinicians considering the trade-offs
between risks and beneﬁts of mattress allocation and frequency of
repositioning decisions.
The trial was planned as a double-triangular group sequential trial,
however, independent monitoring of the event rate and a slower than
planned recruitment rate led to a funder requested unplanned interim
analysis and trial modiﬁcation with one ﬁnal analysis.
Due to clinical difﬁculties in concealing the mattress type, a limi-
tation was the lack of blind outcome assessment. However, the
blinded central photograph review did not identify any systematic
bias concerns as a result of the lack of blinding. This work will under-
pin the design of blinded endpoint assessment in future trials.
Interpretation of the trial results is based on the primary endpoint
at post treatment 30 days ﬁnal follow-up with the treatment phase
sensitivity analysis used to support these ﬁndings. This is the ﬁrst
study to include a longer-term perspective post-treatment phase fol-
low-up [7]. The treatment phase endpoint could be considered more
clinically meaningful due to the majority of Category 2 PUs devel-
oping within this phase (83%), the relevance of the outcome to the
institution providing the mattress intervention and the different
patient pathways following the treatment phase and associated dis-
charge. However, the longer term outcome provides a realistic esti-
mate of effectiveness within current in-patient and community
services.
52 J. Nixon et al. / EClinicalMedicine 14 (2019) 4252In high risk patients (acutely ill in-patients who were bedfast/chair-
fast and/or had an existing Category 1 PU or pain on a PU skin site), we
found insufﬁcient evidence of a difference in PU development at the
end of trial follow-up. However, APMs did confer a small treatment
phase beneﬁt. Overall the APM compliance and very low PU incidence
rate observed (7.9%) and small differences between mattresses indi-
cates the need for improved indicators for targeting of APMs and indi-
vidualised decision making taking into account patient preferences
(comfort/movement ability), rehabilitation needs and the presence of
risk factors whichmay be modiﬁable through APM allocation.
Future research should consider the primacy given to treatment
phase endpoint, an updated estimate of the event rate, and focusing
on groups of patients identiﬁed as potentially beneﬁtting more from
APM compared to HSF to conﬁrm whether there is a true treatment
effect in these groups. However it is recognised that recruitment to a
trial in these patient groups is likely to be challenging based on the
experiences of this trial.
The ﬁndings provide the RCT evidence to underpin current guide-
lines which recommend the use of HSF for patients at risk of PU and
consideration of ‘high tech’ mattresses where HSF is failing. This study
will inform recommendation revisions and the grade of evidence on
which recommendations are based. Current device regulations fall
short in the requirement for evidence of clinical effectiveness and can
result in widespread adoption of ‘high tech’ solutions prior to demon-
strated clinical or patient beneﬁt.
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